As of 2026-10-14, the Relative Valuation of Neovacs SA (ALNEV.PA) is (280.04) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 0.18 EUR, the upside of Neovacs SA based on Relative Valuation is -153966.4%.
The range of the Relative Valuation is (339.72) - (236.88) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 5.8x - 7.7x | 6.8x |
| Forward P/E multiples | 11.1x - 12.0x | 11.6x |
| Fair Price | (339.72) - (236.88) | (280.04) |
| Upside | -186757.6% - -130255.9% | -153966.4% |
| Date | P/E |
| 2026-10-09 | -0.01 |
| 2026-10-08 | -0.01 |
| 2026-10-07 | -0.01 |
| 2026-10-06 | -0.01 |
| 2026-10-05 | -0.01 |
| 2026-10-02 | -0.01 |
| 2026-10-01 | -0.01 |
| 2026-09-30 | -0.01 |
| 2026-09-29 | -0.01 |
| 2026-09-28 | -0.01 |
| 2026-09-25 | -0.01 |
| 2026-09-24 | -0.01 |
| 2026-09-23 | -0.01 |
| 2026-09-22 | -0.01 |
| 2026-09-21 | -0.01 |
| 2026-09-18 | -0.01 |
| 2026-09-17 | -0.01 |
| 2026-09-16 | -0.01 |
| 2026-09-15 | -0.01 |
| 2026-09-14 | -0.01 |
| 2026-09-11 | -0.01 |
| 2026-09-10 | -0.01 |
| 2026-09-09 | -0.01 |
| 2026-09-08 | -0.01 |
| 2026-09-07 | -0.01 |
| 2026-09-04 | -0.01 |
| 2026-09-03 | -0.01 |
| 2026-09-02 | -0.01 |
| 2026-09-01 | -0.01 |
| 2026-08-31 | -0.01 |
| 2026-08-28 | -0.01 |
| 2026-08-27 | -0.01 |
| 2026-08-26 | -0.01 |
| 2026-08-25 | -0.02 |
| 2026-08-24 | -0.02 |
| 2026-08-21 | -0.02 |
| 2026-08-20 | -0.02 |
| 2026-08-19 | -0.02 |
| 2026-08-18 | -0.02 |
| 2026-08-17 | -0.02 |
| 2026-08-14 | -0.02 |
| 2026-08-13 | -0.02 |
| 2026-08-12 | -0.03 |
| 2026-08-11 | -0.03 |
| 2026-08-10 | -0.04 |
| 2026-08-07 | -0.04 |
| 2026-08-06 | -0.02 |
| 2026-08-05 | -0.02 |
| 2026-08-04 | -0.02 |
| 2026-08-03 | -0.03 |